What stage does Polaris Partners invest at?

Polaris Partners invests at the Seed, Series A, Series B, Series C, Growth stages.

What is Polaris Partners's typical check size?

Polaris Partners typically writes checks of $500K – $5M.

What sectors does Polaris Partners focus on?

Polaris Partners focuses on Biotech, Consumer, Digital Health, Healthtech.

Where is Polaris Partners located?

Polaris Partners is headquartered in Boston, US.

Polaris Partners

Venture capitalActively deploying

Boston · Seed–Growth · 43 people tracked

Also known as Polaris Growth Fund · POLARIS GROWTH MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Polaris Partners emphasizes real partnership as the foundation for building great companies. For nearly three decades, the firm has collaborated with talented biotech and healthcare entrepreneurs, backing transformational companies in these fields. Its approach centers on doing well by working together with founders throughout the company-building journey.

Invests inBiotech Consumer Digital Health HealthtechAsia-PacificBostonEuropeUnited States

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Growth

Check

$500K – $5M

Boston, Massachusetts, US

Instruments

Equity

Founded

1995

AUM

$4.2B

Tracked investments

Team · 43 people

from the firm's website & public directories

Jon Flint· Founding Partner· Massachusettsin 𝕏

Jon Flint co-founded Polaris Partners with Steve Arnold and Terry McGuire in 1996. He began his venture career in 1984 at Burr, Egan, Deleage & Co., where he became a General Partner and helped build the firm's technology portfolio, having previously worked as a litigation associate at the Boston law firm Testa, Hurwitz and Thibeault and served on research teams for the Nixon Impeachment Inquiry Staff and the Watergate Special Prosecution Force. In 2005 he conceived of and co-founded Living Proof, and in 2015 he and Terry McGuire formed Polaris Founders Capital to invest their own capital across stages and sectors.

j•••@polarispartners.comreveal

Terry McGuire· Founding Partner· Massachusettsin

t•••@polarispartners.comreveal

Alan Crane· Entrepreneur Partner

Alan Crane joined Polaris Partners in 2002 as an entrepreneur partner, focusing on building and investing in healthcare companies. He has held founder, CEO, and Chairman roles across ten Polaris companies, including co-founding Zag Bio, Seismic Therapeutic, and Dyno Therapeutics, and founding Pandion Therapeutics (acquired by Merck). He was previously president and CEO of Momenta Pharmaceuticals (acquired by J&J) and SVP of corporate development at Millennium Pharmaceuticals, and holds degrees from Harvard College, Harvard Graduate School of Arts & Sciences, and Harvard Business School.

a•••@polarispartners.comreveal

Alexandra Cantley· Managing Partner· New York, New Yorkin 𝕏

Alexandra Cantley is a managing partner at Polaris Partners, which she joined in 2019, working from the New York office with a focus on early-stage biotech and healthcare investments. Before Polaris, she was part of the initial research team at Inzen Therapeutics and previously held a research fellowship at Vertex Pharmaceuticals. She holds a PhD in Chemical Biology from Harvard University and completed her undergraduate studies at New York University.

Amir Nashat· Entrepreneur Partner· Cambridge, Massachusettsin 𝕏

Amir Nashat is an entrepreneur partner in Polaris Partners' Boston office who joined the firm in 2002 and serves as a managing partner of Polaris Funds VI–IX. He focuses on portfolio company executive roles and investing in healthcare companies, and is currently CEO of Souffle Therapeutics. He earned an ScD in Chemical Engineering with a minor in Biology at MIT as a Hertz Fellow under Robert Langer, and holds MS and BS degrees in Materials Science and Mechanical Engineering from UC Berkeley.

a•••@polarispartners.comreveal

Amy Schulman· Managing Partner· Mount Pleasant, South Carolinain

Amy Schulman is a managing partner at Polaris Partners focused on healthcare companies and early stage biotech startups. She joined the firm in 2014 and co-founded the Polaris Innovation Fund in 2017, which she continues to manage. Before Polaris she held roles at Pfizer including general counsel and president of Pfizer Nutrition and Pfizer Consumer Healthcare, was a partner at DLA Piper, and began her career at Cleary Gottlieb Steen & Hamilton; she is also a Senior Lecturer at Harvard Business School and holds degrees from Wesleyan University and Yale Law School.

a•••@polarispartners.comreveal

Brendan Hannigan· Entrepreneur Partner

b•••@polarispartners.comreveal

Brian Chee· Managing Partner· San Francisco, Californiain 𝕏

Brian Chee is a managing partner at Polaris Partners in San Francisco who invests in healthcare companies. He joined Polaris as an associate in Boston shortly after the firm's founding in 1996, and previously worked at Goldman Sachs in New York and San Francisco and at Baxter Healthcare, where he developed experience across medical devices, pharmaceuticals, and biotechnology. He holds a BS from the United States Military Academy at West Point and an MBA from the Tuck School of Business at Dartmouth College, and served as a Captain in the US Army Corps of Engineers.

b•••@polarispartners.comreveal

Bryce Youngren· Managing Partner· Waltham, Massachusettsin 𝕏

Chen-Ee Lee· Partner

Dan Lombard· Managing Partner· Boston, Massachusettsin

Darren Carroll· Partner· Boston, Massachusettsin

Ellie McGuire· Managing Partner· Boston, Massachusettsin

Ellie McGuire is a managing partner in Polaris Partners' Boston office and manages the Polaris Innovation Fund, which she co-founded. Before Polaris, she was head of business development at Lyndra and held leadership and consulting roles in business development, operations, and strategy at life science companies including Arsia Therapeutics, SQZ Biotechnologies, and XTuit Pharmaceuticals. She also serves as an expert in residence for the Harvard Office of Technology Development.

e•••@polarispartners.comreveal

Gary Swart· Operating Partner· Athertonin 𝕏

Gary Swart is an operating partner at Polaris Partners in San Francisco, where he invests in healthcare services and products. He previously served as CEO of oDesk (later Upwork), which merged with Elance, and earlier held roles as Chief Revenue Officer of Intellibank and a business unit executive at IBM following its acquisition of Rational Software. He also mentors at accelerators including Alchemist and StartX.

g•••@polarispartners.comreveal

Jonathan Ang· Entrepreneur Partner· Singapore

Jonathan Ang joined Polaris Partners in 2023 as an entrepreneur partner in the firm's Singapore office, where he focuses on investing in, building, and scaling healthcare companies. Previously he was a Director on the Life Sciences Team at Temasek International in Singapore, managing its global healthcare services investment strategy and co-leading investments across multiple regions. He began his career on Cowen's Health Care Banking Team in New York and London, and holds an honors degree in Economics from The Wharton School of the University of Pennsylvania.

Sabrina Chiasson· Partner· Boston, Massachusettsin

Brian Lewis· Director, Legal & Investment Analytics· San Franciscoin

Brian Lewis joined Polaris in 2019 as director of legal and investment analytics in the firm's San Francisco office, where he handles investment analytics projects along with legal operations and deal matters. He previously worked at Latham & Watkins LLP, first as a senior paralegal and then as a quantitative analysis manager in the corporate department, supporting financial and capitalization modeling for equity financings, acquisitions, and IPOs. He holds a BS in Mathematics from UCLA, a paralegal certification from San Francisco State University, and an MBA from UC Berkeley's Haas School of Business.

Joanna Zesiger· Director of Finance

Leah Paquette· Director of Operations and LP Relationsin

Marissa Bertorelli· Principal· San Francisco, Californiain 𝕏

Mark Jacobson· Principal· Boston, Massachusettsin

Nil Gural· Principal· New York

Nil Gural is a principal at Polaris Partners, which she joined in 2022, where she works on biotech and healthcare investments. She previously was a manager in Bain & Company's healthcare practice covering pharma and medical devices, and earlier was part of the founding team at Glympse Bio, contributing to its platform technology. She holds a PhD from the Harvard-MIT HST program, where she was an HHMI fellow, and a BS in Biomedical Engineering from Washington University in St. Louis.

Paulina Hill· Principal𝕏

Noel Ruane· Venture Partner𝕏

Pat Kinsel· Venture Partnerin 𝕏

Annie Wihongi· Executive Assistant and Office Manager

Daniel Anderson· Scientific Advisory Committee Member

Dave Barrett· Senior Advisory Partner· Boston, Massachusettsin 𝕏

Dave Barrett is a senior advisory partner in Polaris Partners' Boston office who focuses on healthcare technology. He joined Polaris in 2000 after an operating career that included serving as COO of Calico, SVP of worldwide operations at Pure Atria/Rational Software, and various leadership roles over 12 years at Lotus Development. He also serves as a managing partner of Polaris Funds VI-IX and the Polaris Healthcare Technology Opportunities Fund, with particular interest in AI and ML platforms for care management.

d•••@polarispartners.comreveal

Elizabeth Dowd· Executive Assistant and Office Manager· Boston

Elizabeth Dowd joined Polaris in 2018 as an executive assistant and office manager in the firm's Boston office. Before Polaris, she provided administrative support to various non-profits and worked as a tour guide at historic sites.

Harold Friedman· Chief Financial Officerin

h•••@polarispartners.comreveal

Joanne Trayers· Executive Assistantin

JoAnne Trayers joined Polaris Partners in 2001 as executive assistant to co-founder Jon Flint on the technology side of the firm, and more recently moved to the healthcare team supporting Alan Crane. Before Polaris, she supported the CEO and CFO at Allaire Corporation, worked with the senior management team at Powersoft Corporation, and served as operations manager at FirstSense Software.

Kara Greenwood· Executive Assistant· New York

Kara Greenwood joined Polaris in 2023 as an executive assistant supporting the firm's New York office. She has worked as a c-suite executive assistant across various industries, with prior roles supporting executives at Goldman Sachs, SBE Entertainment, a private family office, and Virtue Labs. She holds a BS in Communications from The University of Tennessee Knoxville.

Kirti Anand· Fund Controller

Kirti Anand joined Polaris in 2022 as fund controller, where she handles fund management and reporting. She previously worked as an Audit Senior Manager at BDO in the asset management group, focusing on alternative investments across venture capital and private equity clients. She is a Certified Public Accountant (Inactive) and holds a Master of Accounting degree from Golden Gate University.

Lauren Crockett· General Counsel and Chief Compliance Officer· San Franciscoin

Lauren Crockett is general counsel and chief compliance officer at Polaris Partners, which she joined in 2019, handling legal, compliance, and operational matters including fundraising, fund management, and deal structuring. She previously served as assistant general counsel at LendingClub Corporation and was a corporate associate at Latham & Watkins, and earlier held legal and government affairs roles at Bain Capital. She holds a JD from Harvard Law School and a BA in history from Dartmouth College.

Liz Wong· Executive Assistant and Office Manager· San Francisco

Liz Wong joined Polaris Partners in 2025 as executive assistant and office manager for the firm's San Francisco office. She previously provided administrative and office management support to finance, advertising, and tech companies including FCB Global, Vantage Point Capital, and Intuit.

Manik Kuchroo· Senior Associate

Maureen St. Pierre· Portfolio Analyst· Boston, Massachusettsin

Maureen St. Pierre joined Polaris Partners in 2002 as a portfolio analyst supporting the finance and investor relations teams. Before Polaris, she worked in auditing, budget and cost accounting, and investment pension financial management at John Hancock Financial Services. She holds a BS in Finance from Siena College and an MBA from Babson College.

Megan Jahan· Accounting Manager· San Francisco

Megan Jahan is the accounting manager at Polaris Partners, which she joined in 2018 in the San Francisco office, working with the finance team on management company accounting. She previously spent over fourteen years in various accounting positions at VantagePoint Capital Partners. She holds a degree in Administrative Office Management from Renton College.

Michelle Pizzi· Senior Operations Associate· Boston

Michelle Pizzi joined Polaris Partners' Boston office in 2019 as a senior operations associate, where she supports the operations team's initiatives. She previously spent five years at The Fulham Group, managing the office and working with the finance department, and earlier held support roles at Mercer. She holds a BA in marketing with a minor in finance from Assumption College.

Molly Wilson· Executive Assistantin

Molly Wilson joined Polaris in 2002 as executive assistant to co-founder and general partner Terry McGuire. Since 2010, she has co-founded and served as executive administrator for the Global Venture Capital Congress, organizing its annual meetings of venture capital associations worldwide. Her earlier career included executive assistant roles supporting leadership at EMC Corporation, Arch Wireless, Oak Industries, and Brandeis University, and she is a graduate of The Katharine Gibbs School in Boston.

Pat Mulach· Vice President· Boston, Massachusettsin 𝕏

Robert Langer· Scientific Advisory Committee Member

Sean Thornton· Office Coordinator· Boston

Sean Thornton joined Polaris Partners' Boston office in 2022 as an office coordinator. Before Polaris, he worked as an assistant office manager at the Above the Rim sports complex.

What they invest in

from 47 of 65 portfolio companies

Biotech ×30AI & Machine Learning ×13Healthtech ×12Enterprise Software ×9Medical Devices ×8SaaS ×4Marketing Tech ×3Cloud Computing ×2

HQs:United States×54Netherlands×1

Investments · 65 tracked

founders shown can be your intro path

Adagio TherapeuticsNASDAQ: IVVDSEC filingmedium confidence

BiotechWaltham, US

Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)Halley Gilbert(Executive Officer)Terrance McGuire(Director)Rebecca Dabora(Executive Officer)Rene Russo(Director)

Board seatTerry McGuireTerrance G. McGuire· per SEC Form D · $23.7M raise · filed Nov 2022

aTYR PHARMAatyrpharma.comNASDAQ: ATYRSEC filingmedium confidence

aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.

BiotechHealthtechMedical DevicesSan Diego, US

Amir Nashat(Non-Management Director)Paul Schimmel(Non-Management Director)Akkaraju Srinivas(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Ed Penhoet(Non-Management Director)

Board seatAmir Nashat· per SEC Form D · $76.3M raise · filed Apr 2015

Camp4 Therapeutics CorpNASDAQ: CAMPSEC filingmedium confidence

BiotechCambridge, US

RICHARD YOUNG(Director)MICHAEL HIGGINS(Director)JORGE CONDE(Director)JOSH MANDEL-BREHM(Executive Officer, Director)

Board seatAmir Nashat· per SEC Form D · filed Jun 2022

Cartesian Therapeutics (NASDAQ: RNAC)cartesiantherapeutics.comin 𝕏NASDAQ: RNACSEC filingmedium confidence

Cartesian Therapeutics develops mRNA-based cell therapies for autoimmune diseases.

BiotechHealthtechWatertown, US

Metin Kurtoglu(Executive Officer)Chris Jewell(Executive Officer)Carsten Brunn(Executive Officer, Director)Emily English(Executive Officer)Blaine Davis(Executive Officer)Stephen Smolinksi(Executive Officer)

Board seatAmir Nashat· per SEC Form D · $70M raise · filed Jan 2020

Cyclerion TherapeuticsNASDAQ: CYCNSEC filinghigh confidence

BiotechCambridge, US

Ole Isacson(Director)Stephanie Lovell(Director)Terrance McGuire(Director)Amy Schulman(Director)Marsha Fanucci(Director)George Conrades(Director)

Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $24.3M raise · filed Aug 2020

Dare BioscienceNASDAQ: DARESEC filingmedium confidence

BiotechSan Diego, US

MarDee Haring-Layton(Chief Accounting Officer)Sabrina Martucci Johnson(President and Chief Executive Officer)Christopher D.T. Guiffre(Executive Officer, Director)Gregg Beloff(Executive Officer)Alejandra V. Carvajal(Executive Officer)Adrian Senderowicz(Executive Officer)

Board seatAlan Crane· per SEC Form D · $1 raise · filed Oct 2016

Fate TherapeuticsNASDAQ: FATESEC filingmedium confidence

BiotechSan Diego, US

Amir Nashat(Director)John Mendlein(Director)Christian Weyer(Executive Officer, Director)William Rastetter(Director)J. Scott Wolchko(Executive Officer)Mark Enyedy(Director)

Board seatAmir Nashat· per SEC Form D · $10.3M raise · filed Aug 2016

Fractylfractyl.comin 𝕏NASDAQ: GUTSSEC filingmedium confidence

Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.

BiotechHealthtechMedical DevicesLexington, US

ALLAN WILL(Director)STANLEY LAPIDUS(Director)NIMESH SHAH(Director)CHRISTOPHER GABRIELI(Director)HARITH RAJAGOPALAN(Executive Officer, Director)JAY CAPLAN(Executive Officer, Director)

Board seatAmy Schulman· per SEC Form D · $20.1M raise · filed Jan 2022

Ironwood PharmaceuticalsNASDAQ: IRWDSEC filingmedium confidence

BiotechCambridge, US

LAWRENCE S. OLANOFF(Director)TERRANCE G. MCGUIRE(Director)MARK G. CURRIE(Executive Officer)EDWARD P. OWENS(Director)JULIE MCHUGH(Director)HALLEY E. GIBLERT(Executive Officer)

Board seatTerrance G. Mcguire· per SEC Form D · $150M raise · filed Oct 2016

PulmatrixNASDAQ: PULMSEC filingmedium confidence

BiotechFramingham, US

Anand Varadan(Director)Richard Batycky(Director)Michael Higgins(Director)Peter Ludlum(Interim CEO; Interim CFO)Christopher Cabell(Director)Todd Bazemore(Director)

Board seatTerrance McGuire· per SEC Form D · $3.7M raise · filed Dec 2018

Tectonic TherapeuticNASDAQ: TECXSEC filingmedium confidence

BiotechWatertown, US

Timothy Springer(Director)Alise Reicin(Executive Officer, Director)Daniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)Peter McNamara(Executive Officer)Marcella K. Ruddy(Executive Officer)

Board seatTerry McGuire· per SEC Form D · $80.1M raise · filed Apr 2021

VaccinexOTC: VCNXSEC filingmedium confidence

BiotechRochester, US

Maurice Zauderer, Ph.D.(Director, Executive Officer)Elizabeth Evans(Executive Officer)Ernest S. Smith Ph.D.(Executive Officer)Jill Sanchez(Executive Officer)J. Jeffrey Goater(Director)Barbara Yannni(Director)

Board seatAlan Crane· per SEC Form D · $18.2M raise · filed Jul 2017

X4 PharmaceuticalsNASDAQ: XFORSEC filinghigh confidence

BiotechBoston, US

Mary DiBiase(Executive Officer)Murray W. Stewart(Director)Christophe Arbet-Engels(Executive Officer)David Kirske(Executive Officer)Michael S. Wyzga(Director)John Volpone(Executive Officer)

Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $50.5M raise · filed May 2017

Leyden Labsleydenlabs.comin✓ verified

Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses at the nasal mucosa to prevent initial infection and transmission.

BiotechHealthtechMedical DevicesLeiden, NL

Koenraad Wiedhaup(Founder and Chief Executive Officer)inRonald Brus(Founder and Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)in

1366 TechnologiesSEC filingmedium confidence

Bedford, US

Yasheng Huang(Director)Franciscus J.A. van Mierlo(Executive Officer, Director)Bruce Sohn(Director)Reidar Langmo(Director)Robert Metcalfe(Director)Carmichael Roberts(Director)

Board seatAmir Nashat· per SEC Form D · $30M raise · filed May 2016

480 BiomedicalSEC filingmedium confidence

Watertown, US

Robert Langer(Director)Guido Neels(Director)Maria Palasis(Director, Executive Officer)Terrance McGuire(Director)Richard Mott(Director)Carmichael S. Roberts(Director)

Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Nov 2016

Agbiomeagbiome.comSEC filingmedium confidence

AgTechResearch Triangle Park, US

Scott Uknes(Manager)Larry Robbins(Secretary)Thomas Dietz(Manager)John Ryals(Manager)Kristina Burow(Manager)Paul Schulze-Lefert(President)

Board seatAmir Nashat· per SEC Form D · $117.2M raise · filed Feb 2022

Amagma, Inc.SEC filingmedium confidence

HealthtechWaltham, US

Amy Schulman(Director)Tillman Gerngross(Executive Officer, Director)

Board seatAmy Schulman· per SEC Form D · $10M raise · filed Dec 2022

Athletes' PerformanceSEC filingmedium confidence

Phoenix, US

Mark Verstegen(Executive Officer, Director)Dan Burns(Executive Officer, Director)Peter Hotz(Director)John Stobo(Director)Timothy Kilgallon(Director)Rick Smith(Executive Officer)

Board seatJonathan Flint· per SEC Form D · $193.8K raise · filed Feb 2016

Auron Therapeutics, Inc.SEC filingmedium confidence

Newton, US

Board seatAlexandra Cantley· per SEC Form D · $42.3M raise · filed Dec 2025

Be Me HealthSEC filingmedium confidence

Marblehead, US

Scott Cousino(Director)Ronald Geraty(Executive Officer, Director)

Board seatAlexandra Cantley· per SEC Form D · $8.2M raise · filed Nov 2022

Blue Rabbit VenturesSEC filingmedium confidence

BiotechPortland, US

Benjamin J. Shaw(Executive Officer, Director)Edward L. Cahill(Director)Terrance G. McGuire(Director)

Board seatTerrance G. McGuire· per SEC Form D · $14.5M raise · filed Apr 2021

ByHeartbyheart.comSEC filingmedium confidence

HealthtechNew York, US

Georg Krause-Vilmar(Executive Officer)Amy Schulman(Director)Hemi Zucker(Director)Guy Oranim(Director)Arie Belldegrun(Director)Anton Linderum(Director)

Board seatAmy Schulman· per SEC Form D · $95.5M raise · filed May 2026

Cardurion Pharmaceuticals, Inc.SEC filingmedium confidence

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)Nicholas Downing(Director)

Board seatAmy Schulman· per SEC Form D · $17.5M raise · filed Dec 2022

Cirrus Therapeutics, Inc.SEC filingmedium confidence

Cambridge, US

Andrew Dick(Director, Promoter)Khoo Shih(Director)Ying Kai Chan(Executive Officer, Director, Promoter)

Board seatAlexandra Cantley· per SEC Form D · $15.7M raise · filed Aug 2025

Crossbow Therapeuticscrossbowtx.cominSEC filingmedium confidence

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inAlexandra Cantley(Director)inDmitri Wiederschain(Executive Officer)inSakae Asanuma(Director)inCharles Baum(Director)inIrena Melnikova(Director)in

Board seatAlexandra Cantley· per SEC Form D · $80M raise · filed Sep 2025

Dewpoint Therapeuticsdewpointx.cominSEC filingmedium confidence

BiotechBoston, US

Regina Barzilay, Ph.D.(Director)Guiseppe A. Ciaramella, Ph,D.(Director)Mark Murcko, Ph.D.(Director)Amir H. Nashat, Ph.D.(Director)Olivier Brandicourt, M.D.(Director)Richard Young, Ph.D.(Director)

Board seatAmir Nashat· per SEC Form D · $150M raise · filed Feb 2022

Drizlydrizly.comSEC filingmedium confidence

On-demand alcohol delivery platform providing consumers with a better way to shop for wine and spirits

Sherborn, US

Walt Doyle(Director)Barkley Stuart(Director)James Cory Rellas(Executive Officer)Pat Kinsel(Director)Paul Purcell(Director)Justin Robinson(Executive Officer)

Board seatPat Kinsel· per SEC Form D · $34.6M raise · filed Dec 2018

Epi Biologicsepibiologics.cominSEC filingmedium confidence

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical Devices

BoardMichael Kavanaugh(Founding Advisor)

Board seatAlexandra Cantley· per SEC Form D · $73M raise · filed Apr 2024

Freenome HoldingsSEC filingmedium confidence

Philadelphia, US

Charles Roberts(Director)Gabriel Otte(Executive Officer, Director)

Board seatAmir Nashat· per SEC Form D · $270M raise · filed Aug 2020

Glympse Bioglympsebio.comSEC filingmedium confidence

BiotechCambridge, US

Theresia Guow(Director)Sirshendu Roopom Banerjee(Executive Officer)Gabriel Kwong(Executive Officer)Stan Lapidus(Director)Amy Schulman(Director)

Board seatAmy Schulman· per SEC Form D · $18M raise · filed Dec 2021

Icelandic ProvisionsSEC filinghigh confidence

New York, US

Hallbjorn Karlsson(Director)Sigurjon Rafnsson(Director)Jonathan Flint(Director)David Albertsson(Director)Mark Alexander(Executive Officer, Director)Trausti Jonsson(Director)

Board seatTerrance McGuire· per SEC Form D · $9.1M raise · filed Jan 2017

Jnana Therapeutics Inc.SEC filingmedium confidence

Boston, US

Board seatTerrance G. McGuire· per SEC Form D · $50M raise · filed Aug 2021

LyndraSEC filingmedium confidence

BiotechWatertown, US

Carlo Giovanni Traverso(Director)Zafi Avnur(Director)Amy W. Schulman(Executive Officer, Director)Edmund Harrigan(Director)Catherine Reynolds(Director)Robert S. Langer(Director)

Board seatAmy Schulman· per SEC Form D · $206.1M raise · filed Dec 2023

Microchips BiotechSEC filingmedium confidence

HealthtechLexington, US

Richard Mott(Director)John Isaacsohn(Director)Robert S. Langer(Director)David Neafus(Executive Officer)Cheryl R. Blanchard(Executive Officer, Director)Stephen N. Oesterle(Director)

Board seatTerrance G. McGuire· per SEC Form D · $18.6M raise · filed Jun 2015

Morphic Holding, Inc.SEC filingmedium confidence

BiotechWaltham, US

Barbara Dalton(Director)Ramy Farid(Director)Kevin Bitterman(Director)Praveen Tiprirneni(Executive Officer, Director)Timothy Springer(Director)Vikas Goyal(Director)

Board seatAmir Nashat· per SEC Form D · $100M raise · filed Mar 2023

Nomad Healthnomadhealth.comin

Nomad Health operates a job marketplace for travel nurses and allied health professionals, connecting clinicians with positions that match their experience and preferences while providing dedicated support throughout the hiring and credentialing process.

B2B MarketplacesHealthtechHR TechNew York, US

Tom Bremner(Director)Thomas Mawhinney(Director)Alexander Nazem(Director)Justin Lambert(Executive Officer, Director)Ralph Henderson(Director)William Eager(Vice President of Engineering)

Board seatBrian Chee· per SEC Form D

Picturenoetik.aiin 𝕏SEC filingmedium confidence

NOETIK builds AI and computational biology platforms to discover and develop cancer therapeutics by combining large-scale multimodal spatial biology data from human tumors with machine learning models.

AI & Machine LearningBiotechHealthtechSouth San Francisco, US

Jacob Rinaldi(Executive Officer, Director, Promoter)Ronald Alfa(Executive Officer, Director, Promoter)SVP, Head of Research at Recursion(Co-founder)VP of Informatics at Parker Institute for Cancer Immunotherapy(Co-founder)Chief Corporate Development Officer at Recursion(Co-founder)

BoardJames Hardiman(Director)

Board seatAmy Schulman· per SEC Form D · $40M raise · filed Aug 2024

Podimetricspodimetrics.cominSEC filingmedium confidence

Podimetrics develops a remote monitoring solution combining the SmartMat device and personalized support to identify high-risk individuals with complex diabetes and enable early intervention to prevent complications.

Digital HealthHealthtechMedical DevicesSomerville, US

David Linders(Executive Officer, Director)Jonathan Bloom(Executive Officer, Director)

BoardAaron Sandoski(Director)

Board seatAlexandra Cantley· per SEC Form D · $60M raise · filed Apr 2022

Primmune Therapeutics, Inc.SEC filingmedium confidence

San Diego, US

Board seatAmir Nashat· per SEC Form D · $24M raise · filed Nov 2020

Pulmatrix OperatingSEC filingmedium confidence

BiotechLexington, US

Kurt Graves(Director)Steven Gillis(Director)Robert Connelly(Director)Michael Higgins(Director)David Edwards(Director)Terrance McGuire(Director)

Board seatTerrance McGuire· per SEC Form D · $34.1M raise · filed Jun 2015

Quralisquralis.comin 𝕏SEC filingmedium confidence

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Laia Crespo-Martin(Director)Shafique Virani(Executive Officer)Johannes Fruehauf(Director)

Board seatAmy Schulman· per SEC Form D · $24.9M raise · filed Sep 2025

Seismic Therapeutic, Inc.SEC filingmedium confidence

Watertown, US

Board seatAlan Crane· per SEC Form D · $146.3M raise · filed Sep 2024

SequelaeSEC filingmedium confidence

Minneapolis, US

Albert Zimmerli(Director)Rushika Fernandopulle(Director)Sara Taylor(Executive Officer)Mike Christy(Executive Officer)Gregory Johnson(Executive Officer)Ken Ehlert(Executive Officer, Director)

Board seatAmy Schulman· per SEC Form D · $1.5M raise · filed Nov 2025

Seventh Sense BiosystemsSEC filingmedium confidence

BiotechCambridge, US

PETER HUTT(Director)ALAN CRANE(Director)ROBERT LANGER(Director)R. ROX ANDERSON(Director)HOWARD BERNSTEIN(Executive Officer)ANUPENDRA SHARMA(Director)

Board seatAlan Crane· per SEC Form D · $10M raise · filed Sep 2017

Sofregen MedicalSEC filingmedium confidence

BiotechCambridge, US

Milan Kofol(Executive Officer)Doug Sheldon(Director)Anh Hoang(Executive Officer)Howard Weisman(Executive Officer, Director)Amir Nashat(Director)

Board seatAmir Nashat· per SEC Form D · $9.7M raise · filed Sep 2017

SunBird Bio, Inc.SEC filingmedium confidence

Cambridge, US

Board seatAlexandra Cantley· per SEC Form D · $23.2M raise · filed May 2023

Syros Pharmaceuticals, Inc.SEC filingmedium confidence

Cambridge, US

Board seatAmir Nashat· per SEC Form D · $121.6M raise · filed Dec 2020

TRex Holdings Inc.SEC filingmedium confidence

BiotechSouth San Francisco, US

M. Johnston Erwin Jr.(Executive Officer, Director)

BoardEric Pham(Director)Travis Coy(Director)Carol Gallagher(Director)Joel Marcus(Director)Michael Ross(Director)

Board seatAlexandra Cantley· per SEC Form D · $85M raise · filed Nov 2024

Allstacksallstacks.comin

Allstacks is an AI-agent platform that connects data from software development tools (Jira, GitHub, GitLab, Jenkins) to provide engineering teams and leaders with delivery metrics, risk alerts, and recommendations for planning, managing, and optimizing software creation.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareRaleigh, US

Jeremy Freeman(Founder)Hersh A. Tapadia(Executive Officer, Director)Darrell J. Freeman, Jr.(Executive Officer, Director)Scot Sherwood(Director)Jack Klinck(Director)

BoardAndrew Drylie(Director)

Baxter Planningbaxterplanning.comin

Baxter Planning provides software and services for service supply chain management, serving enterprises managing complex operational logistics and supplier networks.

AI & Machine LearningEnterprise SoftwareLogistics & Supply ChainSaaS

Anton Chilton(Chief Executive Officer)in

Boxeversitecore.comin 𝕏

Sitecore provides a content management and customer experience platform that uses AI to help brands manage content, data, and personalized digital experiences across multiple channels.

AI & Machine LearningEnterprise SoftwareMarketing Tech

Dyno Therapeuticsdynotx.comin 𝕏

Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.

AI & Machine LearningBiotechWatertown, US

Eric Kelsic(CEO & Cofounder)Sam Sinai(Vice President, Head of ML & Cofounder)Adrian Veres(Chief Scientific Officer & Cofounder)George Church(Scientific Cofounder)Tomas Bjorklund(Scientific Co-founder)Alan Crane(Executive Chairman & Cofounder, Polaris Entrepreneur Partner)

Egnyteegnyte.comin 𝕏

Egnyte provides software for protecting and managing business-critical content across organizations of all sizes.

AI & Machine LearningCloud ComputingCybersecurityEnterprise Software

Vineet Jain(Chief Executive Officer)

Folxfolxhealth.comin 𝕏

FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.

Digital HealthHealthtech

A.G. Breitenstein(Founder)Lynne Chou O'Keefe(Director)Lena Ballantine(Executive Officer)Liana M Guzman Weis(Executive Officer, Director)Morgan Cheatham(Director)Lee Shapiro(Director)

Jibejibe.comin 𝕏

ICIMS is an enterprise-grade applicant tracking system and AI-powered recruitment software that helps talent acquisition teams streamline hiring through candidate sourcing, relationship management, and automated workflows.

AI & Machine LearningEnterprise SoftwareHR TechSaaS

KSQ Therapeuticsksqtx.comin 𝕏

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

GEORGE GOLUMBESKI(Director)RICHARD A. MOSCICKI, PH.D.(Director)ALAN L. CRANE(Director)JAMES GILBERT(Director)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)

Loblob.comin 𝕏

Lob provides software and hardware infrastructure for automating, personalizing, and tracking direct mail campaigns at scale.

Enterprise SoftwareLogistics & Supply ChainMarketing TechSaaSNew York City, US

Eduardo Browne(Executive Officer)Donnell Vanker(Executive Officer)

Localyticslocalytics.cominacquired by Upland Software

Localytics is an AI implementation firm that builds, integrates, and operates marketing AI systems for enterprise consumer brands.

AI & Machine LearningEnterprise SoftwareMarketing TechSaaSBoston, US

John Dobrowolski(CEO)inDerick Thompson(VP of Operations)inJuan Yrigoyen(Head of Product)inJoey Rahman(Head of Engineering)Carl Jones(CTO)

LogEntrieslogentries.comin 𝕏

Rapid7's Incident Command is a cloud-native security information and event management (SIEM) platform that combines logs, telemetry, and asset data to provide threat detection and response capabilities for security operations centers.

AI & Machine LearningCloud ComputingCybersecurityData & InfrastructureEnterprise Software

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Fund performance · per public LP disclosures · 3

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Polaris Growth FundLPs: Los Angeles City Employees' Retirement System, Pension Reserves Investment Management Board	2018	—	36.8%	2.86x	0.57x
Polaris Partners VIIILPs: Hawaii Employees' Retirement System, Los Angeles City Employees' Retirement System	2017	—	15.8%	2.08x	1.10x
Polaris Partners VIILPs: Los Angeles City Employees' Retirement System, Hawaii Employees' Retirement System	2014	—	8.5%	1.88x	0.68x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

What stage does Polaris Partners invest at?: Polaris Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
What is Polaris Partners's typical check size?: Polaris Partners typically writes checks of $500K – $5M.
What sectors does Polaris Partners focus on?: Polaris Partners focuses on Biotech, Consumer, Digital Health, Healthtech.
Where is Polaris Partners located?: Polaris Partners is headquartered in Boston, US.

Media · Podcasts & interviews

featuring the team

Tech Investing Mastermind: Terry McGuire- Co-founder of Polaris Partners & Chairman Emeritus of NVCA - YouTube

Grace Gong · Terry McGuire

Fireside Chat with Robert Langer (KI) and Terry McGuire (Polaris Partners) - YouTube

KochInstituteMIT · Terry McGuire

Co-investors · 137

Andreessen Horowitz

Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.

$500K – $50M

General Catalyst

General Catalyst is a venture capital and investment firm that backs founders across industries, with a strong focus on AI-driven transformation, fintech, healthcare, and other sectors.

$30M

GV (Google Ventures)

Google Ventures is a venture capital investor that backs innovative founders across multiple industries, focusing on long-term partnerships and providing value across multiple funding stages and company milestones.

$250K – $50M

Lightspeed Venture Partners

Lightspeed Venture Partners is a global venture capital firm known for backing AI and technology founders, emphasizing deep, hands-on partnerships with the companies it funds.

$1.7M – $87M

Bessemer Venture Partners

Bessemer Venture Partners is a venture capital firm that partners with entrepreneurs from early stages through every stage of growth, publishing investment roadmaps across multiple technology sectors.

$5M – $100M

Khosla Ventures

Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.

$5K – $50M

Greylock Partners

Greylock Partners is a venture capital firm that backs founders at the earliest stages, often as their first investor before a product exists.

$100K – $200M

Techstars

Techstars is a startup accelerator and early-stage investor that funds ambitious founders and provides capital, mentorship, and access to a global network of investors, operators, and corporate partners.

$220K

Founder Collective

Founder Collective is an early-stage venture capital firm focused on seed and pre-seed investments across all sectors.

Uncork Capital

Uncork Capital is a seed-stage venture firm that backs founders at the earliest stage, before their potential is widely recognized.

$3M – $5M

Insight Partners

Insight Partners is a software-focused investment firm that provides capital and operational support to companies from early to late stage, backed by its in-house Insight Onsite operating team.

$120M – $350M

Benchmark

Benchmark is a venture capital firm with offices in San Francisco and Woodside that invests in early-stage startups.

$100K – $30M

▶125 more co-investors

Felicis Ventures FJ Labs Menlo Ventures Foundation Capital DCVC (Data Collective)Coatue Management B Capital Group Norwest Venture Partners CRV (Charles River Ventures)Canaan Partners Sapphire Ventures Eniac Ventures Goat Capital RRE Ventures NextView Ventures Bling Capital Oak HC/FT C2 Investments Freestyle Capital Headline Scale Venture Partners Obvious Ventures Stellar Capital SoftBank Vision Fund Floodgate Meritech Capital Partners Resolute Ventures Stride VC Bonfire Ventures F-Prime Capital Partners Maveron Next47 Venrock Lowercase Capital 01 Advisors Atlas Venture Harrison Metal US Venture Partners BAM Ventures Accomplice Village Global 75 & Sunny Unusual Ventures Better Tomorrow Ventures Standard Capital NextGen Venture Partners Saga Ventures 23andMe Left Lane Capital Moxxie Ventures Zetta Venture Partners Wildcat Venture Partners ARCH Venture Partners OrbiMed Javelin Venture Partners Breakthrough Energy Ventures Highland Capital Partners foobar.vc Locus Ventures Owl Ventures Hoxton Ventures Scrum Ventures VitalStage Ventures RA Capital Amasia Highbury Holdings BIOSPRING PARTNERS Samsung Next Artis Ventures Flare Capital Partners Ten Eleven GreatPoint Ventures S32 .406 Ventures EQT Life Sciences Versant Ventures SR One Capital Management Strata Capital Partners Forbion 5AM Ventures Johnson & Johnson Innovation – JJDC Pillar VC Sanofi Ventures Ascension Ventures Domain Associates Mithril Capital Management Autotech Ventures Abingworth Asset Management Ventures Market One Capital Firefly Health Flagship Pioneering Pfizer Venture Investments byFounders Digitalis Ventures Kurma Partners Aisling Capital SV Health Investors Republic Capital (ex Republic Labs)Vivo Capital MPM Capital Define Ventures Advent Life Sciences Vinyl Capital Qiming Venture Partners Apollo Health Ventures Alta Partners Vida Ventures Cofounders Capital MPM BioImpact +ND Capital aMoon HealthQuest Capital Medical Excellence Capital RiverVest Venture Pontifax Venture Capital Avoro Capital Advisors Catalio Capital Management, LP Vertex Ventures HC Borealis Ventures Broadview Ventures ACORN BIOVENTURES Mission Biocapital Altitude Ventures Management, Llc 3TS Capital Partners

Firms observed investing alongside Polaris Partners, from public investor directories.

Similar investors

Bessemer Venture Partners

$5M – $100M

General Catalyst

General Catalyst is a venture capital and investment firm that backs founders across industries, with a strong focus on AI-driven transformation, fintech, healthcare, and other sectors.

$30M

Khosla Ventures

Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.

$5K – $50M

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.